Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

55.73USD
28 Aug 2015
Change (% chg)

$-0.43 (-0.77%)
Prev Close
$56.16
Open
$55.76
Day's High
$55.87
Day's Low
$55.29
Volume
330,455
Avg. Vol
288,475
52-wk High
$60.34
52-wk Low
$41.73

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $114,239.90
Shares Outstanding(Mil.): 2,062.56
Dividend: 0.76
Yield (%): 1.36

Financials

  NVO.N Industry Sector
P/E (TTM): 30.87 35.90 36.13
EPS (TTM): 1.80 -- --
ROI: 75.61 15.37 14.83
ROE: 82.48 15.94 15.69
Search Stocks

Novo Nordisk to buy two private pharma research firms

COPENHAGEN - Novo Nordisk said on Thursday it has agreed to buy two private biopharmaceutical research companies specializing in diabetes Calibrium LLC and MB2 LLC.

27 Aug 2015

Novo to begin Phase III trial of oral diabetes treatment

COPENHAGEN - Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that could be taken orally rather than by injection after "encouraging" results in previous trials.

26 Aug 2015

UPDATE 1-Novo to begin Phase III trial of oral diabetes treatment

COPENHAGEN, Aug 26 - Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that could be taken orally rather than by injection after "encouraging" results in previous trials.

26 Aug 2015

Novo to begin Phase III trial of oral diabetes treatment

COPENHAGEN, Aug 26 - Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that would be taken orally rather than by injection after "encouraging" results in previous trials.

26 Aug 2015

BRIEF-Genmab in license agreement with Novo Nordisk

* Enters commercial license agreement with Novo Nordisk for Duobody technology

14 Aug 2015

China gets tougher for Western drugmakers

LONDON - The Chinese market is getting tougher for Western pharmaceutical companies as Beijing bears down on a rising healthcare bill and prices come under pressure.

06 Aug 2015

China gets tougher for Western drugmakers

LONDON, Aug 6 - The Chinese market is getting tougher for Western pharmaceutical companies as Beijing bears down on a rising healthcare bill and prices come under pressure.

06 Aug 2015

Novo Nordisk impacted by U.S. price pressure in H1 -CEO

COPENHAGEN, Aug 6 - Novo Nordisk, the world's largest insulin maker, was impacted by price pressure in the United States in the first half of 2015, its chief executive said.

06 Aug 2015

NORDIC STOCKS - Factors to watch on Aug 6

The following stocks may be affected by newspaper reports and other factors on Thursday:

06 Aug 2015

UPDATE 1-Novo Nordisk lifts full-year profit outlook after strong second quarter

* Q2 Victoza sales up 47 percent to 4.49 billion crowns (Adds detail, background)

06 Aug 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €88.44 -0.12
Eli Lilly and Co (LLY.N) $83.19 -0.55

Earnings vs. Estimates

Search Stocks